Sonrotoclax becomes the first BCL-2 inhibitor approved for relapsed or refractory mantle cell lymphoma, showing over 10-fold greater potency than venetoclax.
- In the news
Chronic Lymphocytic Leukemia Research
Moving in Cancer Discovery.
- Moved this week
- 1
Rebuilt
Moved this week
Latest in Chronic Lymphocytic Leukemia Research
Newest first · last 60 days
In PTPN11-mutant juvenile myelomonocytic leukemia, dual NLRP3 and PTGS2 inhibition combined with MEK blockade significantly prolongs survival and reduces leukemic burden in models.
- Open access
IL-16-driven signaling mediates resistance to BTK inhibitors and R-CHOP in B-cell lymphomas, with IL-16 upregulation observed in resistant cases.
- Open access
- 6 cites
Ibrutinib improves event-free survival in early-stage CLL patients with certain genetic mutations but offers no overall survival benefit across all subgroups.
Elevated SYTL4 expression is linked to poorer prognosis and may serve as a diagnostic, prognostic, and therapeutic biomarker in DLBCL, with a hazard ratio of 25.541.
- Open access
Follow this area in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4